Research · Peptide synopsis

TB-500 (Thymosin β4) — the actin-sequestering tissue-repair peptide

Wellness Labs Editorial·26 May 2026·8 min read

TB-500 is shorthand for an acetylated synthetic fragment of Thymosin β4 — a 43-amino-acid protein discovered in bovine thymus tissue in 1981 and now recognised as the dominant intracellular G-actin-sequestering peptide in mammalian cells. The “TB-500” name comes from the lab nomenclature of a research-grade synthetic version; in the published literature you will see the parent compound, Thymosin β4 (Tβ4), much more often.

What TB-500 actually is

Thymosin β4 is a 43-amino-acid protein, molecular weight ~4.9 kDa. It was first isolated from bovine thymus tissue in 1981 by Goldstein and colleagues, who were screening thymic peptides for immune-modulating activity. It later became clear that Tβ4 is one of the most abundant intracellular proteins in mammalian cells (concentrations in the 100-200 µM range in many tissue types) and that its primary intracellular role is to sequester G-actin monomers — controlling the pool of polymerisable actin available for cytoskeletal dynamics.

“TB-500” is a research-grade synthetic peptide marketed as containing the active fragment of Tβ4. In practice, the “TB-500” sold by research-peptide suppliers is most commonly the full 43-residue Thymosin β4 sequence, acetylated at the N-terminus to match the post-translationally-modified native protein. Some suppliers offer the shorter N-terminal 17-residue fragment that contains the actin-binding motif (LKKTETQ); both forms appear in the preclinical literature, and the activity profiles are broadly similar in cell-culture and animal-injury models.

What the mechanism research shows

The mechanism literature splits into two parallel stories — intracellular vs extracellular Tβ4:

Intracellular: G-actin sequestering. Tβ4 binds G-actin monomers via the LKKTETQ motif, keeping them out of the polymerised F-actin pool. This regulates cell migration, cytokinesis, and cytoskeletal remodeling. Most of the protein’s house-keeping biology runs through this single mechanism.
Extracellular: angiogenesis and tissue repair. Tβ4 released from injured cells (or administered exogenously) signals through cell-surface receptors to promote endothelial-cell migration, capillary formation, and recruitment of stem/progenitor cells to injury sites [1]. The angiogenic-mechanism work is the most-cited body of evidence for the regenerative-medicine claims [2].

Honest take: the intracellular actin-sequestering role of Tβ4 is textbook cell biology. The extracellular regenerative biology is interesting and reasonably well-supported in animal models, but the human-trial translation has been slower than the preclinical signal suggested.

What the preclinical animal data shows

Animal-model studies of exogenous Tβ4 administration have demonstrated effects across an unusually wide range of injury contexts:

Wound healing. The foundational 1999 study in mouse full-thickness dermal wounds demonstrated that topical or systemic Tβ4 accelerated re-epithelialisation and increased granulation-tissue formation [3]. This was the result that drove the RegeneRx clinical-trial program.
Cardiac repair. Systemic Tβ4 administration after myocardial infarction in rodent models has been reported to promote both myocardial-cell survival and vascular regeneration — a dual-mechanism effect rare among single-peptide interventions. The 2019 review in Frontiers in Pharmacology consolidates this evidence [4].
Skeletal muscle. Muscle injury induces local Tβ4 release; exogenous Tβ4 acts as a chemoattractant for myoblasts and accelerates muscle regeneration [5].
Corneal injury, central nervous system injury, and hair-follicle regeneration are smaller bodies of evidence with consistent positive signals but smaller sample sizes.

The clinical-trial history

RegeneRx Biopharmaceuticals (later RegeneRx Inc.) ran a multi-year clinical-trial program for Tβ4 across dermal-ulcer, corneal-wound, and dry-eye indications. The trials reached phase-2 readouts in several indications and showed efficacy signals, but the company did not advance to phase-3 registration trials and did not file for FDA approval. Tβ4 therefore remains a research-grade compound — no approved therapeutic indication in any major jurisdiction.

The most-cited subsequent clinical interest has been in the cardiac-repair context. The dual myocardial-survival + angiogenic profile is uncommon among regenerative-medicine candidates, and several academic groups continue to investigate Tβ4 in cardiac-injury models as a potential adjunct to revascularisation. As of 2026 no late-stage cardiac-indication trial has been registered with FDA approval as the endpoint.

The UAE research-supply landscape

TB-500 is supplied in the UAE as a lyophilised powder, most commonly 2 mg or 5 mg per vial. The compound is stable when stored lyophilised at -20°C; reconstituted in bacteriostatic water, the literature suggests stability at 2-8°C for 2-4 weeks. Quality variation across the research-peptide category is substantial — full 43-residue Tβ4 is a longer synthesis than most peptides on the market and the purity controls separate good suppliers from grey-market repackagers. The 5 mg research-consultation page covers the analytical disclosure framework we apply per lot.

Open questions

Open questions in the published literature:

Why the RegeneRx trials did not advance. The phase-2 efficacy signals were positive but the regulatory program stopped short of phase-3. Whether this reflects business decisions, trial-design issues, or material-effect-size concerns is not clear from the public record.
The receptor pathway for extracellular Tβ4. Multiple candidate receptors have been proposed (purinergic, integrin-linked) but no single high-affinity receptor has been pinned down with the resolution available for, say, melanocortin-receptor pharmacology.
Whether the shorter “TB-500” 17-residue fragment is equivalent to full Tβ4 in vivo. Most published animal-model work uses full Tβ4; the commercial “TB-500” supply is sometimes the fragment. Direct head-to-head comparisons in the literature are sparse.
Long-term safety. The phase-2 trial safety profile was clean at the doses studied (mg/day range), but chronic-administration data over years does not exist.